首页> 外文期刊>Clinical and experimental hypertension: CEH >Efficacy of thrombolytic (rt-PA) therapy in old stroke patients: the Perugia Stroke Unit experience.
【24h】

Efficacy of thrombolytic (rt-PA) therapy in old stroke patients: the Perugia Stroke Unit experience.

机译:老年卒中患者溶栓(rt-PA)疗法的疗效:佩鲁贾卒中病房经验。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

The use of intravenous recombinant tissue plasminogen activator (rt-PA) administered within 3 hrs from symptom onset is beneficial in selected patients independent of age; although oldest patients (> or = 80 years) are excluded a priori. We report an experience relative to rt-PA treatment in the oldest patients including outcome at 3 months. Data were from the hospital-based Perugia Stroke Registry. Seventy-two consecutive acute stroke patients, fulfilling NINDS and EUSI-criteria were treated with rt-PA of these 23 patients (30.5%) were > or = 80 years. The median and mean age were, respectively, 72.5 and 71.1 +/- 12.7 years (range 35-94). The proportion of favorable outcome at 3-months did not differ between groups (55% elderly versus 51.1% of younger patients). Proportions of unfavorable outcome and death from baseline were similar in both groups of patients. Age did not influence prognosis in patients treated with rt-PA. The oldest stroke patients should not be excluded from rt-PA treatment on the basis of age per se.
机译:在症状发作后3小时内使用静脉重组组织纤溶酶原激活剂(rt-PA)有益于不受年龄限制的特定患者;尽管年龄最大的患者(>或= 80岁)被先验排除。我们报道了在年龄最大的患者中接受rt-PA治疗的相关经验,包括3个月时的预后。数据来自医院的佩鲁贾中风登记处。 rt-PA治疗了72例符合NINDS和EUSI标准的连续急性中风患者,其中23例(30.5%)≥80岁。中位年龄和平均年龄分别为72.5岁和71.1 +/- 12.7岁(范围35-94)。各组在3个月时的良好结局比例没有差异(老年患者为55%,年轻患者为51.1%)。两组患者的不良结局和基线死亡的比例相似。年龄不影响接受rt-PA治疗的患者的预后。根据年龄本身,不应将年龄最大的中风患者排除在rt-PA治疗范围之外。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号